Table 3. 12-Month clinical outcomes.
Cilostazol (n=205) | Aspirin (n=408) | P value | OR | 95% CI | |
---|---|---|---|---|---|
MACE [n (%)] | 10 (4.9%) | 34 (8.3%) | 0.118 | 0.56 | 0.27–1.17 |
Cardiac death | 2 (0.98%) | 3 (0.74%) | 0.755 | 1.33 | 0.22–7.81 |
Restenosis | 3 (1.5%) | 20 (4.9%) | 0.035 | 0.29 | 0.09–0.98 |
Myocardial infarction | 4 (1.9%) | 14 (3.4%) | 0.306 | 0.56 | 0.18–1.72 |
Stroke [n (%)] | 1 (0.49%) | 0 | 0.158 | -- | -- |
TVR | 5 (2.4%) | 15 (3.7%) | 0.416 | 0.65 | 0.23–1.83 |
Bleeding | 1 (0.49%) | 11 (2.7%) | 0.063 | 0.18 | 0.02–1.38 |